Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
13:38 EDT 9 Aug 2012 | Elsevier Business Intelligence
Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.
Original Article: Alexza Expects FDA, EU Regulatory Decisions On Adusave This December
More From BioPortfolio on "Alexza Expects FDA, EU Regulatory Decisions On Adusave This December"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
